Document is current
Any future updates will be listed below
-
Authors
Molina, Kyle C.
Webb, Brandon J.
Kennerley, Victoria
Beaty, Laurel E.
Bennett, Tellen D.
Carlson, Nichole E.
Mayer, David A.
Peers, Jennifer L.
Russell, Seth
Wynia, Matthew K.
Aggarwal, Neil R.
Ginde, Adit A.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525, UL1TR002525)
- License Information
-
More Information
Article History
Received: 2 September 2023
Accepted: 2 August 2024
First Online: 8 August 2024
Declarations
:
: This study was approved by the Colorado Multiple Institutional Review Board (COMIRB). The requirement for informed consent was waived by COMIRB provided a lack of feasibility to retrospectively consent patients.
: Not applicable.
: Not applicable.
: KCM reports honoraria for serving on the speakers bureau for Melinta Therapeutics, Innoviva Specialty Therapeutics, and Shionogi Inc. NRA reports grants from the US National Institutes of Health (NIH), during the conduct of the study. TDB reports grants from the NCATS, during the conduct of the study, and grants from the NICHD and NHLBI, outside of the submitted work. NEC reports grants from the US NIH, during the conduct of the study. AAG reports grants from the US NIH during the conduct of the study, grants from the US Centers for Disease Control, the US Department of Defense, AbbVie, and Faron Pharmaceuticals, and participation on an NIH data safety monitoring board, outside of the submitted work. All other authors declare no competing interests. All other authors report no conflicts of interest.
: The authors declare no competing interests.
